A federal judge on Tuesday allowed part of a shareholder lawsuit against Novo Nordisk A/S to proceed. The judge ruled that investors have a reasonable basis to claim that the company's statements regarding the tolerability and clinical trial design of its CagriSema drug may have been misleading.
This ruling does not constitute a finding of securities fraud against Novo Nordisk. It simply moves the case to the next phase, allowing investors to gather evidence to support their claims. A spokesperson for Novo Nordisk responded by stating the company believes the allegations are entirely without merit and will vigorously defend itself.
The lawsuit arrives at a critical time for Novo Nordisk, as it faces increasing competition from Eli Lilly and works to bolster investor confidence in its obesity business while heavily investing in a new generation of weight-loss drugs. Below is a breakdown of the case, the investors' claims, and why CagriSema is crucial for the company's future.
Core of the Investor Lawsuit
The lawsuit centers on the experimental drug CagriSema, a once-weekly combination therapy containing semaglutide (the active ingredient in Wegovy and Ozempic) and cagrilintide, which mimics the hormone amylin. In December 2024, Novo Nordisk released pivotal data from a CagriSema clinical trial. The market had widely anticipated an average weight loss of around 25%, but the actual result was only 20.4%, causing a sharp drop in the company's stock price.
Shareholders allege that prior to the data release, the company failed to adequately inform investors that the REDEFINE-1 trial used a flexible dosing regimen, allowing participants to adjust their doses, rather than requiring all to reach the maximum dose. Only 57% of participants ultimately received the highest dose. Investors further claim that Novo Nordisk created the impression that the Phase 3 REDEFINE-1 trial followed the same fixed-dose approach as earlier studies, using a steady dose of 2.4 mg of semaglutide and 2.4 mg of cagrilintide.
Investors argue that this insufficient disclosure about the key dosing information led the market to misinterpret the clinical trial results, particularly regarding the tolerability of the drug at the highest dose. The court noted that a patient's ability to consistently continue on a target dose, or tolerability, is a critical metric for obesity treatments, making the difference between the two dosing approaches significant. In a 56-page opinion, Judge Robert Kirsch wrote, "Clinical trials are detailed and involve many variables; a conference call for investors is not a professional academic symposium." However, he emphasized that drug companies cannot deliberately distort key clinical trial information or omit important details to mislead.
Novo Nordisk denies any wrongdoing. Court documents show that on the day of the December data release, Novo Nordisk's American Depositary Receipts fell by $18.15 per share, a drop of 17.83%, with over 53 million shares traded. Shares listed in Copenhagen dropped by 20.7%.
Scope of the Judge's Ruling
The judge dismissed most of the shareholders' claims, ruling that investors failed to prove that many of the company's statements about CagriSema's weight-loss potential and future trial plans met the legal standard for actionable misrepresentation. However, the claims related to CagriSema's tolerability and the REDEFINE-1 clinical trial protocol were allowed to proceed.
The court acknowledged that investors have a reasonable basis to argue that some descriptions of the trial design were potentially misleading, including the characterization of REDEFINE-1 as a fixed-dose combination trial. Statements by Martin Holst Lange, Novo Nordisk's former Executive Vice President for Development and current Chief Science Officer, regarding the drug's tolerability and dosing regimen were also deemed questionable. The judge also found that investors had provided sufficient evidence of intent, a necessary standard for holding Lange accountable. The court noted that Lange was consistently presented by the company as the key executive responsible for explaining clinical trial design and results to investors.
This ruling does not confirm the validity of the allegations; it only confirms that the legal claims meet the criteria to proceed through the judicial process.
Why CagriSema is Pivotal
This lawsuit comes at a time of significant pressure for Novo Nordisk. While the company pioneered the modern obesity drug market with Wegovy and Ozempic, it faces increasing competition from Eli Lilly, which is rapidly gaining market share. A group of Novo Nordisk shareholders is now suing the company, targeting the experimental drug CagriSema. They allege that the company misled investors by withholding key trial information before releasing disappointing clinical data, which resulted in a loss of tens of billions of dollars in market value.
Intense competition makes the company's drug development pipeline increasingly critical for investors. Novo Nordisk is relying on several products, including a high-dose version of Wegovy, an oral formulation, and CagriSema, to solidify its market position. The company has positioned CagriSema as a key upgrade in its obesity drug pipeline, frequently emphasizing to investors its potential for more significant weight loss with manageable side effects.
Novo Nordisk does not view the initial clinical data as a failure. Earlier this year, CEO Mike Doustdar stated that the market's reaction to the data was an overreaction and overly pessimistic, and that further trials will fully demonstrate the drug's true potential.
This Shareholder Lawsuit is Separate from Novo Nordisk's Suit Against Eli Lilly
This shareholder lawsuit is not related to the recent commercial dispute filed by Novo Nordisk against Eli Lilly. Last week, Novo Nordisk sued Eli Lilly, alleging unfair competition in its advertising. The claim is that Eli Lilly's ads compare its drugs to older, lower-dose versions of Novo Nordisk's products, without including the latest clinical data for the high-dose version of Wegovy. Eli Lilly has denied all allegations, stating that its advertising is based on published clinical research.
The two cases focus on entirely different issues. The lawsuit against Eli Lilly concerns competitive marketing practices, while the shareholder lawsuit against Novo Nordisk centers on the company's compliance with information disclosure rules when communicating the CagriSema trial design and results to investors. The shareholder lawsuit is now in the discovery phase, where investors will gather evidence to try to prove that Novo Nordisk violated U.S. securities laws. Novo Nordisk can continue to present its defense before a formal trial begins.
Comments